Akums Drugs saw its shares dip over 4% in morning trading following mixed Q2 FY25 results.
The company reported a 12.5% year-over-year (YoY) drop in revenue, posting ₹1,033.09 crore for the quarter ended September 30, 2024, compared to ₹1,181.24 crore in Q2 FY24. However, revenue showed a slight 1.4% increase quarter-over-quarter (QoQ) from ₹1,019.13 crore in Q1 FY25.
Net profit, on the other hand, soared. Akums recorded ₹66.65 crore in profit for Q2 FY25, marking a 103.8% YoY increase from ₹32.69 crore and an 8.9% QoQ rise from ₹61.21 crore in the prior quarter.
For the first half of FY25, revenue reached ₹2,052.20 crore, slightly down from ₹2,151.14 crore YoY. Profit for the six-month period rebounded impressively to ₹127.86 crore, recovering from a ₹154.73 crore loss in the same period last year.
As of 9:37 am, Akums Drugs shares were trading 4.42% lower at Rs 761.00 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
